Capital International Sarl Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Capital International Sarl purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund purchased 23,806 shares of the biotechnology company's stock, valued at approximately $3,277,000.

Several other large investors also recently made changes to their positions in the company. Rice Hall James & Associates LLC increased its holdings in shares of Ascendis Pharma A/S by 2.0% during the fourth quarter. Rice Hall James & Associates LLC now owns 163,888 shares of the biotechnology company's stock valued at $22,562,000 after acquiring an additional 3,274 shares in the last quarter. abrdn plc raised its holdings in Ascendis Pharma A/S by 18.3% during the fourth quarter. abrdn plc now owns 187,180 shares of the biotechnology company's stock worth $25,769,000 after buying an additional 28,967 shares during the last quarter. Exome Asset Management LLC raised its holdings in Ascendis Pharma A/S by 119.2% during the third quarter. Exome Asset Management LLC now owns 43,849 shares of the biotechnology company's stock worth $6,547,000 after buying an additional 23,849 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Ascendis Pharma A/S by 58.0% during the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company's stock valued at $80,000 after buying an additional 214 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in shares of Ascendis Pharma A/S by 540.5% during the fourth quarter. Blue Trust Inc. now owns 506 shares of the biotechnology company's stock valued at $76,000 after buying an additional 427 shares during the last quarter.

Analysts Set New Price Targets

A number of research firms have issued reports on ASND. Evercore ISI lifted their price target on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research note on Tuesday, February 18th. Morgan Stanley set a $180.00 price objective on shares of Ascendis Pharma A/S in a report on Tuesday, February 18th. The Goldman Sachs Group raised their price target on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. UBS Group assumed coverage on shares of Ascendis Pharma A/S in a research report on Tuesday, January 7th. They issued a "buy" rating and a $196.00 price objective for the company. Finally, Royal Bank of Canada began coverage on shares of Ascendis Pharma A/S in a research report on Wednesday, April 16th. They set an "outperform" rating and a $205.00 target price on the stock. Two research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $204.67.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND traded down $1.89 during trading hours on Thursday, hitting $156.25. The company had a trading volume of 135,501 shares, compared to its average volume of 485,817. The firm has a 50 day simple moving average of $153.31 and a 200 day simple moving average of $138.53. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $169.37. The firm has a market capitalization of $9.53 billion, a price-to-earnings ratio of -22.00 and a beta of 0.54.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. On average, research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.